Form 8-K - Current report:
SEC Accession No. 0000950170-24-125526
Filing Date
2024-11-12
Accepted
2024-11-12 16:30:15
Documents
12
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inab-20241112.htm   iXBRL 8-K 42976
2 EX-99.1 inab-ex99_1.htm EX-99.1 173660
  Complete submission text file 0000950170-24-125526.txt   347119

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inab-20241112.xsd EX-101.SCH 25964
14 EXTRACTED XBRL INSTANCE DOCUMENT inab-20241112_htm.xml XML 4926
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 241448845
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)